BC
FATE icon

Broadfin Capital’s Fate Therapeutics FATE Stock Holding History

Broadfin Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,113,986
Closed -$3.75M – 80
2015
Q4 		$3.75M Hold
1,113,986
– – 0.23% 74
2015
Q3 		$5.94M Sell
1,113,986
-186,014
-14% -$1.27M 0.33% 63
2015
Q2 		$8.41M Buy
1,300,000
+1,229,572
+1,746% +$7.36M 0.45% 51
2015
Q1 		$344K Buy
+70,428
New +$349K 0.03% 82

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Broadfin Capital's FATE Position: Q1 2016 in Review

Broadfin Capital sold out of Fate Therapeutics (FATE) in Q1 2016, closing a stake of 1,113,986 shares — an estimated $3.75M sold.

Broadfin Capital first reported a position in FATE in Q1 2015 and held it in 4 quarters. The position peaked at $8.41M in Q2 2015. 46 funds tracked by Wall St. Rank hold FATE as of Q1 2016.

  • Broadfin Capital reported no remaining Fate Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Broadfin Capital sold 1,113,986 Fate Therapeutics shares in Q1 2016, an estimated $3.75M.
  • Broadfin Capital first reported a position in Fate Therapeutics in Q1 2015 and held it in 4 quarters.
  • Broadfin Capital's Fate Therapeutics position peaked at $8.41M in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.